Baseline characteristics of all enrolled patients
| Total N=49 | |
| Male sex; n (%) | 38 (77.6) |
| Median age (range), years | 61 (40–78) |
| ECOG PS score; n (%) | |
| 0 | 30 (61.2) |
| 1 | 19 (38.8) |
| Prior nephrectomy; n (%) | 46 (93.9) |
| Histology; n (%) | |
| Clear cell | 49 (100) |
| PD-L1 status*; n (%) | |
| Negative <1% | 31 (63.3) |
| Positive ≥1% | 14 (28.6) |
| Unknown | 4 (8.2) |
| IMDC risk group; n (%) | |
| Favorable | 17 (34.7) |
| Intermediate | 22 (44.9) |
| Poor | 10 (20.4) |
| Prior radiotherapy; n (%) | 7 (14.3) |
| Time from initial diagnosis to start of study treatment, median years (range) | 1.57 (0.1–18.4) |
| Stage at initial diagnosis; n (%) | |
| I | 8 (16.3) |
| II | 9 (18.4) |
| III | 9 (18.4) |
| IV | 18 (36.7) |
| Unknown | 5 (10.2) |
| Time from diagnosis of metastasis or locally advanced disease to start of study treatment, median months (range) | 2.1 (0.7–48.8) |
Data cut-off: January 8, 2021.
*PD-L1 status by immunohistochemistry: PD-L1-negative defined as <1% tumor cell staining; PD-L1-positive defined as ≥1% tumor cell staining.
ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic RCC Database Consortium; PD-L1, programmed death ligand-1.